Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
CARBAMAZEPINE
TARO PHARMACEUTICALS INC
N03AF01
CARBAMAZEPINE
200MG
TABLET (CHEWABLE)
CARBAMAZEPINE 200MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0108674001; AHFS:
APPROVED
2001-08-28
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TARO- CARBAMAZEPINE Carbamazepine Tablets Tablets, 200 mg, Oral Taro Standard Pr TARO- CARBAMAZEPINE CHEWABLE TABLETS Carbamazepine Chewable Tablets Chewable Tablets, 100 mg and 200 mg, Oral Pr TARO- CARBAMAZEPINE CR Carbamazepine Extended-Release Tablets Extended-Release Tablets, 200 mg and 400 mg, Oral Taro Standard Pr TARO- CARBAMAZEPINE Carbamazepine Oral Suspension Oral Suspension, 100 mg / 5 mL, Oral USP Anticonvulsant For Symptomatic Relief of Trigeminal Neuralgia Antimanic ATC code: N03AF01 Taro Pharmaceuticals Inc. Date of Initial Authorization: 130 East Drive May 06, 1998 Brampton, Ontario L6T 1C1 Date of Revision: March 3, 2022 Control No: 255034 _ TARO-CARBAMAZEPINE PRODUCT MONOGRAPH PAGE 2 OF 54_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 03/2022 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 03/2022 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations; 4.5 Missed Dose 03/2022 7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics 03/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................................... 2 TABLE OF CONTENTS ......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................. 4 1 INDICATIONS ............................................................................................................................. 4 1.1 Pediatrics ............................................................................................................................... 4 1.2 Geriatrics................................................................................................................................ 5 2 CONTRAINDICATIONS ...................................................................... Կարդացեք ամբողջական փաստաթուղթը